Xiamen, Aug 26, 2026 — China’s deputy drug regulator Lei Ping opened the 16th International Conference on Medical Device Supervision and Administration, pledging to deepen review reforms, tighten full-lifecycle quality controls, and align the sector with the nation’s 15th Five-Year Plan innovation targets as Beijing seeks to advance its high-end medical device industry.
Conference Snapshot
| Attribute | Detail |
|---|---|
| Event | 16th International Conference on Medical Device Supervision and Administration in China |
| Location | Xiamen, Fujian Province |
| Date | Aug 26, 2026 |
| Key officials | Lei Ping, Deputy Commissioner, National Medical Products Administration (NMPA); Wu Bin, Vice Governor of Fujian Province |
| Attendees | Domestic and international regulators, international organizations, industry associations, academic institutions, medical device enterprises |
Regulatory Priorities
Lei outlined the NMPA’s strategic focus across four pillars:
- Review reform — Sustained deepening of medical device evaluation and approval system reforms to accelerate market access.
- Innovation support — Full backing for high-end medical device research, development, and commercialization.
- Lifecycle oversight — Strengthened quality supervision across the entire product lifecycle.
- Global engagement — Expanded international regulatory cooperation and technical exchange.
15th Five-Year Plan Alignment
Lei signaled that the NMPA will anchor its next-phase agenda to the 15th Five-Year Plan development goals, emphasizing that high-efficiency regulation will serve as the foundation for high-level safety, industrial innovation, and high-quality sector growth. The framework aims to translate regulatory capacity into improved public health outcomes.
Bilateral and Industry Engagement
During the conference, Lei held a bilateral meeting with Sulyvong Chokinnaly, Deputy Director-General of the Lao Food and Drug Administration, and participated in roundtable discussions with domestic and international medical device enterprise representatives. The sessions focused on regulatory convergence, market access, and cross-border quality assurance cooperation.
Market Impact Analysis
The Xiamen summit underscores Beijing’s dual-track strategy for the medical device sector: accelerating innovation pathways for domestic high-end manufacturers while tightening quality guardrails through full-lifecycle oversight. Lei’s emphasis on 15th Five-Year Plan alignment suggests forthcoming regulatory reforms will prioritize breakthrough technologies—such as implantable devices, AI-enabled diagnostics, and advanced imaging systems—through streamlined approval channels.
For multinational device makers, the expanded international cooperation agenda signals potential convergence opportunities with China’s regulatory standards, though full-lifecycle oversight commitments imply intensified post-market surveillance obligations. The bilateral engagement with Lao regulators also highlights China’s ambition to export regulatory frameworks and capacity-building support to Southeast Asian markets, potentially smoothing market entry for Chinese device manufacturers in the Mekong region.
Forward-Looking Statement
Industry analysts expect the NMPA to roll out detailed 15th Five-Year Plan implementation guidelines for medical device supervision by late 2026 or early 2027, likely including dedicated fast-track pathways for breakthrough devices and enhanced digital surveillance infrastructure for post-market adverse event monitoring. The Xiamen conference’s focus on high-end innovation suggests regulatory capital will flow toward cardiovascular, neurological, and robotic surgery device segments, where China is seeking to reduce import dependence. Companies with pipeline candidates in these categories should prepare for accelerated review timelines coupled with stricter clinical evidence requirements.-China Health Reform Pulse
Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/hyxx/ylqxhyxx/20260826181534121.html